close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Processa Pharmaceuticals, Inc. - Common Stock (NQ:PCSA)

2.380 +0.210 (+9.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Processa Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
From Processa Pharmaceuticals, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Update on Clinical Programs Enrollment
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming Global Investment Conference
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Names New Key Board Appointments
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q2 2022 Results, Corporate Updates
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2022 Results Conference Call
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Launches New Website Focused on Rare Disease
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) CEO to Present at World Orphan Drug Congress USA
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2022 Report, Updates
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q1 2022 Results, Provide Drug Development Update
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Administers First Dosage in Amended Phase 1B Study
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Enrolls First Patient in PCS12852 Phase 2A Trial
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q4 2021 Results, Provide Clinical Pipeline Update
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Issues Letter to Shareholders Eyeing ‘Transformative Year’ in 2022
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q3 2021 Financial, Corporate Results
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Results of Next-Generation Capecitabine Analysis
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Q3 Results, Development Update Call
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Key Milestone in Clinical Develop Program for PCS12852
Via Investor Brand Network
News headline image
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are... 
From Access to Giving
Via AccessWire
News headline image
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting... 
From Access to Giving
Via AccessWire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today